Showing results (371-380 of 1,406) with videos related to

Sort By:
Pageof 141
Osteoarthritis and Cartilage|December 3, 2020
Visual Analogue Scale has higher assay sensitivity than WOMAC pain in detecting between-group differences in treatment effects: a meta-epidemiological studyBruno R da Costa, Pakeezah Saadat, Reto Basciani, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 21, 2020
Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trialMasafumi Ono, Mariusz Tomaniak, Wolfgang Koenig, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 4, 2023
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)Eliano Pio Navarese, Antonio Landi, Angelo Oliva, et al.
JACC. Cardiovascular Interventions|August 24, 2013
Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trialPatrick W Serruys, Vasim Farooq, Bindu Kalesan, et al.
The American Journal of Cardiology|September 8, 2022
Individual Patient Data Meta-analysis of Drug-eluting Versus Bare-metal Stents for Percutaneous Coronary Intervention in Chronic Versus Acute Coronary SyndromesRaffaele Piccolo, Kaare H Bonaa, Orestis Efthimiou, et al.
JAMA|August 23, 2012
Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trialLorenz Räber, Henning Kelbæk, Miodrag Ostojic, et al.
Heart (British Cardiac Society)|March 22, 2015
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in SwitzerlandRoland Klingenberg, Dik Heg, Lorenz Räber, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 30, 2023
Antithrombotic treatment strategies in patients with established coronary atherosclerotic diseaseMarco Valgimigli, Victor Aboyans, Dominick Angiolillo, et al.
JACC. Basic to Translational Science|November 7, 2022
Translating Imaging Into 3D Printed Cardiovascular Phantoms: A Systematic Review of Applications, Technologies, and ValidationJoël Illi, Benedikt Bernhard, Christopher Nguyen, et al.
Journal of the American Heart Association|October 7, 2022
Therapeutic Management of Anomalous Coronary Arteries Originating From the Opposite Sinus of Valsalva: Current Evidence, Proposed Approach, and the UnknowingMarius Reto Bigler, Alexander Kadner, Lorenz Räber, et al.
Pageof 141